中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 9
Sep.  2016
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(9): 1734-1738

Effect of entecavir combined with Fuzheng Huayu capsules on inflammatory factors and fibrosis markers in patients with compensated chronic hepatitis B-related cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.09.020

  • Department of Liver Disease, The Sixth People′s Hospital of Qingdao

  • Published Date: 2016-09-20
    Abstract
  • Objective To investigate the clinical effect of entecavir( ETV) combined with Fuzheng Huayu capsules in the treatment of patients with compensated chronic hepatitis B- related cirrhosis. Methods A total of 142 patients with compensated chronic hepatitis B- related cirrhosis who visited the Sixth People's Hospital Qingdao from January 2013 to December 2015 were randomly divided into treatment group and control group,with 71 patients in each group. Both groups were given conventional treatment such as liver- protecting and symptomatic treatment. The patients in the control group were given ETV 0. 5 mg/day,while those in the treatment group received oral administration of Fuzheng Huayu capsules 1. 5 g twice a day in addition to the treatment in the control group. Both groups were treated for 12 months. The changes in inflammatory factors and fibrosis markers were observed. The t- test was used for comparison of continuous data between groups,and the chi- square test was used for comparison of categorical data between groups. Results After the 12- month treatment,the treatment group and the control group showed no significant difference in the serum HBV DNA clearance rate [91. 5%( 65/71)vs 90. 1%( 64/71),P = 0. 771]. Compared with the control group,the treatment group showed significant reductions in serum hyaluronic acid,laminin,procollagen type III,collagen type IV,alanine aminotransferase,aspartate aminotransferase,liver stiffness measurement,tumor necrosis factor- α( TNF- α),interleukin- 6( IL- 6),interleukin- 8( IL- 8),and hypersensitive C- reactive protein( hs-CRP)( t = 16. 187,5. 343,13. 697,17. 121,7. 409,27. 371,7. 973,5. 471,7. 885,9. 057,8. 171,all P < 0. 001). Conclusion Compared with ETV alone,ETV combined with Fuzheng Huayu capsules exerts a better anti- fibrotic effect and can inhibit the release of TNF- α,IL- 6,IL- 8 and hs- CRP in patients with compensated chronic hepatitis B- related cirrhosis.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]DONG CF,XIAO J,SHAN LB,et al.Combined acoustic radiation force impulse,aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B[J].World J Hepatol,2016,8(14):616-624.
    [2]YAO J,CHANG L,YUAN L,et al.Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis[J].Asia Pac J Clin Nutr,2016,25(2):283-291.
    [3]PENG CY,CHIEN RN,LIAW YF.Hepatitis B virus-related decompensated liver cirrhosis:benefits of antiviral therapy[J].J Hepatol,2012,57(2):442-450.
    [4]ILOEJE UH,YANG HI,SU J,et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J].Gastroenterology,2006,130(3):678-686.
    [5]CHEN CJ,YANG HI,SU J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA,2006,295(1):65-73.
    [6]ROCHE B,SAMUEL D.Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation:A retrospective study[J].J Hepatol,2009,50(4):719-728.
    [7]KUMADA T,TOYODA H,TADA T,et al.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis[J].J Hepatol,2013,58(3):427-433.
    [8]ABU-AMARA M,FELD JJ.Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?[J].Semin Liver Dis,2013,33(2):157-166.
    [9]TU YY,CHEN HY,LIU XD,et al.Research progress in antiviral therapy for decompensated hepatitis B cirrhosis[J].J Clin Hepatol,2015,31(3):460-464.(in Chinese)涂燕云,陈海艳,刘旭东,等.乙型肝炎肝硬化失代偿期抗病毒治疗的研究进展[J].临床肝胆病杂志,2015,31(3):460-464.
    [10] PU CW,LIU W,LI M,et al.Long term antiviral therapy for chronic hepatitis B can reverse liver cirrhosis[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(4):577-579.(in Chinese)蒲春文,刘威,李梅,等.慢性乙型肝炎的长期抗病毒治疗可逆转肝硬化[J/CD].中华实验和临床感染病杂志:电子版,2014,8(4):577-579.
    [11]SCHIFF ER,LEE SS,CHAO YC,et al.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J].Clin Gastroenterol Hepatol,2011,9(3):274-276.
    [12]ZOUTENDIJK R,REIJNDERS JG,ZOULIM F,et al.Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J].Gut,2013,62(5):760-765.
    [13]ZHANG W,LI QW,LIU YB.Evalution of quality of life and analysis on its correlation with TCM syndrome in patients of Chronic Hepatitis B[J].Chin J Integr Med,2009,15(1):30-33.
    [14]YU Y,GONG R,MU Y,et al.Hepatitis B virus induces a novel inflammation network involving three inflammatory factors,IL-29,IL-8,and cyclooxygenase-2[J].J Immunol,2011,187(9):4844-4860.
    [15] Chinese Society of Hepatology,Chinese Society of Infectious Diseases.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].Chin J Clin Infect Dis,2011,4(1):1-13.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华临床感染病杂志,2011,4(1):1-13.
    [16]LAI JQ,LIU GA,PAN XN,et al.The ultrasonic performance and clinical efficacy of 64 patients with hepatitis B virus-related compensated cirrhosis with the treatment of entecavir combined with Fuzheng Huayu Capsule[J].J Pract Hepatol,2011,14(6):458-459.(in Chinese)赖江琼,刘国安,潘兴南,等.恩替卡韦联合扶正化瘀胶囊治疗64例乙型肝炎肝硬化超声表现及临床疗效分析[J].实用肝脏病杂志,2011,14(6):458-459.
    [17]HONKOOP P,de MAN RA.Entecavir:a potent new antiviral drug for hepatitis B[J].Expert Opin Investig Drugs,2003,12(4):683-688.
    [18]YAO GB,ZHANG DF,WANG BE,et al.A study of the dosage and efficacy of entecavir for treating hepatitis B virus[J].Chin J Hepatol,2005,13(7):484-487.(in Chinese)姚光弼,张定凤,王宝恩,等.恩替卡韦抗乙型肝炎病毒剂量和疗效的研究[J].中华肝脏病杂志,2005,13(7):484-487.
    [19]SEIFER M,HAMATAKE RK,COLONNO RJ,et al.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir[J].Antimicrob Agents Chemother,1998,42(12):3200-3208.
    [20]ZHANG B,HU M,HUANG L,et al.Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis[J].Exp Ther Med,2014,8(4):1123-1126.
    [21]GU J,ZHANG Q,XUE D,et al.A randomized controlled study of fuzheng huayu capsule for prevention of esophageal variceal bleeding in patients with liver cirrhosis[J].Evid Based Complement Alternat Med,2013,2013:534960.
    [22]YU S,GUO Z,GUAN Y,et al.Combining ZHENG theory and high-throughput expression data to predict new effects of Chinese herbal formulae[J].Evid Based Complement Alternat Med,2012,2012:986427.
    [23]LIU P,LIU C,XU LM,et al.Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B[J].World J Gastroenterol,1998,4(4):348-353.
    [24]FAN RQ,SU CZ,ZHU GJ,et al.Therapeutic efficacy of entecavir combined with Fuzheng Huayu capsule in 73 cases of liver fibrosis in chronic hepatitis B[J].Chin J Gastroenterol Hepatol,2013,22(1):31-33.(in Chinese)范瑞琴,苏传真,朱刚剑,等.恩替卡韦联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化73例疗效观察[J].胃肠病学和肝病学杂志,2013,22(1):31-33.
    [25]WU LL.Efficacy of entecavir combined with fuzhenghuayu capsules in treatment of patients with hepatitis B related cirrhosis[J].Mod J Integr Tradit Chin West Med,2013,22(35):3952-3953.(in Chinese)吴龙龙.恩替卡韦联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化疗效观察[J].现代中西医结合杂志,2013,22(35):3952-3953.
    [26]BOSSA AS,SALEMI VM,RIBEIRO SP,et al.Plasma cytokine profile in tropical endomyocardial fibrosis:predominance of TNFa,IL-4 and IL-10[J].PLoS One,2014,9(10):e108984.
    [27]BASINSKA K,MARYCZ K,'SIESZEK A,et al.The production and distribution of IL-6 and TNF-a in subcutaneous adipose tissue and their correlation with serum concentrations in Welsh ponies with equine metabolic syndrome[J].J Vet Sci,2015,16(1):113-120.
    [28]LIU JX,XU B,LIU XX,et al.Correlation of IFN-γand IL-6levels produced by peripheral blood mononuclear cells and HBVDNA load in patients with chronic hepatitis B[J].J Clin Hepatol,2010,26(5):510-512.(in Chinese)刘家秀,徐彬,刘兴祥,等.慢性乙型肝炎患者HBV DNA载量与PMBC分泌IFN-γ、IL-6水平相关性研究[J].临床肝胆病杂志,2010,26(5):510-512.
    [29]ZUO WZ,XU CM,SHEN LC.Changes in serum level of interleukin-32 and interleukin-6 in patients with chronic hepatitis B virus infection and its clinical significance[J].J Clin Hepatol,2011,27(4):408-413.(in Chinese)左维泽,许春梅,沈兰超.乙型肝炎患者血清白细胞介素-32、白细胞介素-6水平变化及临床意义[J].临床肝胆病杂志,2011,27(4):408-413.
    [30]KADAM N,ACHARYA S,SHUKLA S,et al.Ascitic fluid high sensitive C-reactive protein(hs-CRP).A prognostic marker in cirrhosis with spontaneous bacterial peritonitis[J].J Clin Diagn Res,2016,10(4):20-24.
    [31]ZHANG HX,LIU XD,WU HK.Effect of Fuzheng Huayu Capsules on inflammatory factors in patients with chronic hepatitis B cirrhosis[J].Chin J Integr Tradit West Med Liver Dis,2016,26(1):4-5.(in Chinese)张红星,刘旭,吴辉坤.扶正化瘀胶囊对慢性乙型肝炎肝硬化患者炎性因子的影响[J].中西医结合肝病杂志,2016,26(1):4-5.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2394) PDF downloads(457) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return